Key Highlights

  • NewAmsterdam Pharma (NASDAQ:NAMS) reported third-quarter Revenue of USD 19.2 million, versus USD 0.3 million a year earlier, driven by USD 18.3 million of license revenue and USD 0.8 million of Supply revenue.
  • The loss for the period narrowed to USD 17.4 million, or USD 0.14 per share, from USD 72.0 million, or USD 0.61, mainly because a Warrant Fair Value gain of USD 23.1 million replaced a loss of USD 23.8 million.
  • Research and development expenses rose to USD 39.4 million from USD 31.0 million, lifting total operating expenses to USD 63.4 million from USD 55.5 million, while the operating loss narrowed to USD 44.2 million.
  • Cash, cash equivalents and marketable securities were USD 643.1 million at September 30, 2026, and the interim analysis of the PREVAIL outcomes trial is planned for the fourth quarter of 2026.

License Revenue Lifts the Quarter

NewAmsterdam Pharma (NASDAQ:NAMS), a late-stage biopharmaceutical company developing the oral cholesterol-lowering candidate obicetrapib, filed its third-quarter report on November 4, 2026. Revenue was USD 19.2 million against USD 0.3 million a year earlier, and USD 18.3 million of it was license revenue. For the nine months, revenue was USD 25.9 million versus USD 22.5 million, so the quarterly jump partly reflects timing, since the prior-year nine months included USD 22.1 million of license revenue tied to research and development. Under its Menarini license, the company has earned EUR 46 million in milestone payments, of which EUR 16 million arrived in the first nine months of 2026.

Warrant Gain Drives Most of the Smaller Loss

The loss shrank by USD 54.6 million, but the drivers matter. The warrant fair value swing was worth USD 46.9 million, and the company says it now values warrants with a Black-Scholes model that depends mainly on its own share price. Higher revenue helped too. Underneath, spending grew: Research and Development rose USD 8.4 million, including medical affairs costs that were reclassified from selling, general and administrative expenses, which edged down to USD 24.0 million. Interest income fell to USD 5.2 million from USD 6.7 million on a smaller Investment balance, and the quarter included USD 1.2 million of income tax expense on a tax year under review. The nine-month loss was USD 130.0 million versus USD 128.9 million, so the year-to-date loss has not narrowed.

Europe Launch, PREVAIL Interim Look and Liquidity

The European Commission granted Marketing authorization for Ubeslo and Evlarco in September 2026, and the company expects Menarini to launch them in Germany by the end of 2026, with Swiss and UK decisions anticipated later this year. In the United States, the company plans to commercialize obicetrapib itself, if approved. The PREVAIL cardiovascular outcomes trial will have an interim analysis by an independent monitoring board in the fourth quarter of 2026, with a recommendation expected in the first quarter of 2027; the trial could be stopped early for efficacy or futility, or continue. Topline results from the RUBENS trial are expected around year end 2026. The company reported no share sales under its at-the-market program in the nine months, and 2,420,632 warrants remain outstanding.

Where Things Stand

Revenue leapt because a large license revenue item landed in the quarter, not because product sales scaled. NewAmsterdam Pharma (NASDAQ:NAMS) also benefited from a USD 23.1 million warrant gain, while operating costs rose and the nine-month loss was about flat. The Balance Sheet is strong at USD 643.1 million. The filing gives no price move or consensus. Key markers are the German launch by Menarini, the PREVAIL interim recommendation expected in the first quarter of 2027 and RUBENS topline data.